Experienced pharma executive with extensive experience working in Global & Regional divisions of large and small Speciality Biotechnology Pharmaceuticals with hands on strategy development, operations, business development, strategic alliances, co-development, General Management, commercialisation, R&D, early and late stage clinical development, global launch planning and execution, market access, strategic pricing, reimbursement, marketing and sales experience. Broad range of therapy area experience including respiratory, rare diseases, CNS, dermatology, oncology, hematology, medical devices, vaccines, nephrology, immunology, pain management and infectious diseases. Also experienced consultant with a broad understanding of the pharma industry. I have also demonstrated my commercial ability through building up start up businesses.

Vice President, Medicines Commercialization Leader, Haematology, Global Oncology @ From March 2015 to Present (10 months) United KingdomVP, Medicines Commercialization Leader, Haematology, Global Oncology Franchise @ Delivery of the top line and bottom line ambition of the evolving haematology / oncology portfolio. Member of Global Oncology Leadership team and Global Oncology Compliance champion Leading a cross functional, multi matrix therapy area strategy team that includes R&D, clinical, regulatory, finance, medical affairs, commercial analytics, supply chain and core LOC members; as well as directly managing a team of franchise marketing staff. Accountable for developing and delivering the global product strategy and deliverables enabling core LOCs to execute the strategy and achieve the agreed sales ambition. Assimilates customer insights (including payers) early and regularly to inform the product value proposition and clinical development programme. Monitors the strategic P&L for the medicines and finds ways to deliver overall Product operating profit target. Optimizes supply chain strategy with asset supply chain leader to optimize CoGs and returns. From November 2013 to Present (2 years 2 months) VP, Global Commercial - CNS, Neuro Disorders, Rare Malignancies/Haem-onco, Global Rare Disease Unit @ Responsible for guiding the global commercial strategy for all assets in the CNS, Neuro Muscular Disease, Rare Malignancies and haematology-oncology franchise, from evaluation of new opportunities to early stage assets and late stage development medicines Responsible for the development of the overall Medicine Development Strategy to ensure commercial success across all major markets, and to ensure that patient, physician and payer unmet needs and insights are incorporated into the clinical plan. Responsible for driving all aspects of the global and regional Medicines Vision, commercial planning, including treatment evolution strategy, lifecycle strategy, forecast ambition and investment levels, reimbursement ambition, and for driving the commercial deliverables for all assets in the franchises. Hold full responsibility for all aspects of the global commercial budget and ensuring that the regional budget and resource allocation are appropriate to deliver launch excellence across the globe. From November 2011 to November 2013 (2 years 1 month) london, ukDirector and M&A Transition Lead, Genzyme Transplant & Oncology, Global business unit @ Supporting the establishment and ongoing development of Genzyme's Transplant & Oncology (GTO) Business in EMEA, assisting the GTO BU in maximizing top and bottom line growth with optimum utilization of resources in collaboration with the Country Management structure. Linking the Business Unit global strategies, initiatives and priorities to the countries. Establishing relationships and processes to interface with the country management structure. Managing the integration and transition of business development projects into the EMEA business, leading a multifunctional and cross geographic team. This includes assessing the impact of the acquisition on the overall business, working closely with the BU leadership team, EU management team and country teams to assess what resources, skills and capabilities would be required to support the expanding business as well as assessing the overall P&L. Providing direct strategic and tactical support for acquired haem-oncology assets From August 2008 to November 2011 (3 years 4 months) Snr Consultant @ Project leading and delivering complex consultancy projects for differing companies, ranging from assessment of business models, R&D portfolio management, commercial evaluations, market access, pricing and reimbursement, product launches and growth opportunities across multiple therapy areas (including infectious diseases, immunology, oncology, haematology, rare diseases, pain, respiratory, diabetes, neurosciences, generics & biosimilars) and business challenges. Delivered Marketing Excellence training courses to marketing personnel in large pharmaceutical companies in EU, APAC, Australia and LATAM. From April 2007 to August 2008 (1 year 5 months) Product Director @ Responsible for the GI franchise business for the ex-US markets. Development and execution of GI franchise, product strategic and operational plans as the commercial lead for ex-US markets. This included development of Business Development growth strategies and bringing to market a new and innovative product. Held full P&L responsibilities for the ex-US GI business including in-country OpEx and the roll up and negotiation of annual in-country budgets with the GMs and EU management team including LRP process. Developing and executing launch strategies including market access, pricing and reimbursement. Management of European product teams and strategic alliance product team and key member of the global team. Successful development and execution of pre-launch and launch strategy including development of optimal in-country sales and marketing structures and ‘no go’ decisions. Developed and executed patient focused initiatives which directly impacted treatment approaches by physicians and was recognized by a national award for Innovation. Acted as EU/International Compliance Officer tasked with the development and implementation of guidelines and policies globally, regionally and locally in addition to above duties. Also developed and led a marketing excellence training platform as well as sales skills training in addition to above duties which were adopted across all business groups and countries. Successful management of strategic alliances and partnerships. From June 2005 to April 2007 (1 year 11 months) International Therapy Area Project Lead @ GM responsibilities for the product portfolio inclusive of publication planning, clinical development, life cycle management, regulatory strategies, supply chain and medical communications. Full P&L responsibilities including roll up and negotiation of annual in-country budgets and LRP with the GMs. Development of marketing planning processes and tools across the International division. Managing strategic alliances including searching, appointing and directly managing distributors. Successfully launched the products which all went on to become market leaders. Successfully led and managed distributor relationships and strategic alliances including search, negotiation and signing of contracts. Successfully led & managed the divestment of the dermatology and bio surgery business which continued to perform as market leaders. Awarded the 2005 European Pharmaceuticals Marketing Effectiveness Award (PMEA). Developed a patient focused initiative, raising the hidden impact of post-surgical adhesions. This led to changes in practice by surgeons as well as part of the legal surgical consenting process. Established marketing planning processes across all groups which were later also adopted by the business units. Developed and executed a ’blue-print’ for market access which was adopted by other business groups. Provided support to the launch efforts of the renal team which went on to become the market leader in the EU. From December 2003 to July 2005 (1 year 8 months) Business Unit Manager (Hospital Speciality)/Marketing Planning Manager @ Development and implementation of new product launch plans into novel market areas as well as managing existing products inclusive of sales forecasting and expenditure. Maximising the sales and profit potential of designated products through product life cycles, meeting the agreed business objectives through the implementation of agreed strategies and programmes. Recruitment, training and management of the key account hospital sales team alongside managing available resources. From March 2000 to December 2003 (3 years 10 months) Product Manager @ Product manager responsible for the strategic and tactical support of designated products inc. P&L. From February 1999 to March 2000 (1 year 2 months) Medical Representative @ Territorial responsibilities for products to GPs and hospital doctors. From October 1998 to February 1999 (5 months) Research Scientist (Molecular Oncology/Toxicology) @ Development of assay techniques for molecular oncology research. From June 1995 to October 1995 (5 months) Research Scientist (Diabetes Unit) @ Industry placement as a team member of diabetes research and development project (Avandia). From June 1993 to July 1994 (1 year 2 months) Field Sales Executive/Commercial Manager @ Responsible for the running of my own department, establishing and maintaining client base. From April 1991 to October 1991 (7 months)

PhD, Molecular Toxicology/Oncology @ University of Surrey From 1995 to 1999 B.Sc. (Hons), Biochemistry @ University of Surrey From 1991 to 1995 Richard Jones is skilled in: Hematology, Market Access, Oncology, Dermatology, Nephrology, Medical Devices, Management Consulting, Integration, Transition Management, Business Strategy, Infrastructure Management, Business Modeling, Strategic Partnerships, Strategic Alliances, New Business Development